Horizon Discovery CHOSOURCE platform supports development of immunotherapy for autoimmune diseases
Horizon Discovery Group, a leader in the application of gene editing and gene modulation for cell line engineering, says its cGMP-compliant CHOSOURCE™ platform has played a key role in generating a stable cell line for the development of an immunotherapy for autoimmune diseases. Horizon’s pharmaceutical-grade, stable Chinese Hamster Ovary (CHO) cells delivered high yields of […]
